CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis

Abstract Background CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, has demonstrated significantly improved overall survival in acute myeloid leukemia (AML) compared with 7 + 3, but its impact on cardiac function remains unclear. In a pos...

詳細記述

書誌詳細

主要な著者:	Joshua D. Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Shunsuke Eguchi, Yoshiyuki Orihara, Nalina Dronamraju, Sonja Dhani, Stefan Faderl, Tara L. Lin, Geoffrey L. Uy, Jeffrey E. Lancet, Jorge E. Cortes
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-11-01
シリーズ:	Cardio-Oncology
主題:	Cardiotoxicity CPX-351 7 + 3 Acute myeloid leukemia Ejection fraction Anthracyclines
オンライン･アクセス:	https://doi.org/10.1186/s40959-025-00421-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!